Cargando…
Determination of MIC Quality Control Parameters for Exebacase, a Novel Lysin with Antistaphylococcal Activity
Exebacase (CF-301), a novel, antistaphylococcal lysin (cell wall hydrolase) is the first agent of this class to enter late-stage clinical development (phase 3, NCT04160468) for the treatment of Staphylococcus aureus bacteremia, including right-sided endocarditis. A multilaboratory Clinical and Labor...
Autores principales: | Traczewski, Maria M., Ambler, Jane E., Schuch, Raymond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218745/ https://www.ncbi.nlm.nih.gov/pubmed/33910968 http://dx.doi.org/10.1128/JCM.03117-20 |
Ejemplares similares
-
The Lysin Exebacase Has a Low Propensity for Resistance Development in Staphylococcus aureus and Suppresses the Emergence of Resistance to Antistaphylococcal Antibiotics
por: Oh, Jun, et al.
Publicado: (2023) -
Locally delivered antistaphylococcal lysin exebacase or CF-296 is active in methicillin-resistant Staphylococcus aureus implant-associated osteomyelitis
por: Karau, Melissa, et al.
Publicado: (2022) -
Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase
por: Vila-Farres, Xavier, et al.
Publicado: (2023) -
Activity of Antistaphylococcal Lysin CF-301 against Contemporary Staphylococcus aureus Clinical Isolates from the USA and Europe
por: Oh, Jun, et al.
Publicado: (2017) -
Determination of MIC Quality Control Ranges for Ceftibuten-Avibactam (Fixed 4 μg/mL), a Novel β-Lactam/β-Lactamase Inhibitor Combination
por: Huband, Michael D., et al.
Publicado: (2023)